Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Trial Profile

Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
  • Indications Ewing's sarcoma; Neuroectodermal tumours; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Gradalis
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 23 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 04 Nov 2016 According to Gradalis media release, data summarizing the three-year follow-up will be presented at the Annual Meeting of the Society for Immunotherapy of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top